IceCure Ltd. (TASE: ICCM) today announced the first use of IceSense3, its cryoablation procedure for the removal of breast cancer tumors. The system replaces the need for surgical excision of the tumors.
The first four procedures, out a planned 30 procedures, were successfully carried out at the Kameda Medical Center in Kamogowa, Japan, which is fully financing the trial.
IceCure CEO Hezi Himmelfarb said, "The clinical trial destroyed small cancerous tumors by cryoablation, without the need for a surgical procedure. We believe that cryoablation, using the IceSense3, is an innovative approach best suited for treating small cancerous tumors in the breast."
Studies report that more than 300,000 surgical procedures to remove breast cancer tumors are carried out annually in the US alone. These procedures cost thousands of dollar each, as they require operating rooms and staff, as well as hospitalization and recovery time.
Cryoablation, the removal of tissue through the use of extreme cold, has been used to remove benign and malignant tumors of various kinds for years. IceCure's device is already used for the removal of benign tumors.
IceCure's share price rose 44.3% by midday to NIS 2.88, giving a market cap of NIS 38 million.
Published by Globes [online], Israel business news - www.globes-online.com - on June 3, 2012
© Copyright of Globes Publisher Itonut (1983) Ltd. 2012